The company said it does not expect the observation to have any material impact on its current business operations or existing supplies from the facility.

Shilpa Medicare is a diversified pharmaceutical and biotechnology company engaged in the development and manufacture of complex generics, biologics and active pharmaceutical ingredients (APIs). Through its subsidiary Shilpa Biologicals, the company operates a fully integrated biologics platform spanning development, scale-up and commercial manufacturing at its EU-GMP facility in Dharwad, India.

The pharmaceutical company‘s consolidated net profit jumped 115.19% year-on-year to Rs 100.88 crore in Q1 FY27 from Rs 46.88 crore in the corresponding quarter last year. Revenue from operations increased 44.89% YoY to Rs 465.78 crorereflecting broad-based growth across its API, formulations and biologics businesses.

The counter rallied 6.63% to settle at Rs 1020.90 on the BSE.